No Data
WuHan Hvsen Biotechnology (300871.SZ): The overseas factory has passed GMP.
Glory Network, January 14th丨WuHan Hvsen Biotechnology (300871.SZ) stated in a recent investor relations activity that the company's overseas factory has passed GMP, and is currently applying for production licenses from the local relevant departments. Production can commence once the veterinary drug production license is obtained.
WuHan Hvsen Biotechnology (300871.SZ): Currently, the listed company's main body does not involve the pet Hospital business.
On January 14, Gelonghui reported that WuHan Hvsen Biotechnology (300871.SZ) stated in a recent investor relations activity that the listed company's main business does not involve the Hospital Business, and the actual controller has investments in related businesses. The Hospital Industry has significant market space and growth potential, and the company is closely monitoring developments in this Industry.
WuHan Hvsen Biotechnology (300871.SZ): In 2024, 5 new pet Pharmaceuticals and 2 health products were launched.
On January 14, Gelonghui reported that WuHan Hvsen Biotechnology (300871.SZ) indicated during a recent investor relations activity that 2024 will be an important year for the company's pet pharmaceutical research and development achievements to be realized. The company has recently launched five new pet pharmaceuticals and two health products. Currently, the company has obtained six new veterinary drug registration certificates for pets, with 14 pet pharmaceuticals and 16 pet health products available. As the product matrix continues to expand, the company has established an independent offline sales company for pets and an e-commerce platform to enhance market development efforts.
WuHan Hvsen Biotechnology (300871.SZ): expects a loss of 17 million yuan to 23 million yuan in 2024.
Gelonghui, January 13丨WuHan Hvsen Biotechnology (300871.SZ) announced that it expects a loss of 17 million to 23 million yuan in 2024, a year-on-year turnaround from profit, with a non-recurring loss of 14 million to 19 million yuan. 1. During the reporting period, the sales volume of the company's chemical drug formulation sector achieved year-on-year growth, and sales revenue remained basically flat. However, the decline in product prices led to a decrease in gross margin, which had a certain impact on Net income. 2. The company continues to increase investment in research and development innovation, with research and development expenses rising year-on-year, which has a certain impact on Net income. 3. After the production and solidification of the projects funded by Convertible Bonds, the interest on Convertible Bonds during this reporting period is accounted for.
Huisheng Biotech: 2024 Annual Performance Forecast
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Not Doing Enough For Some Investors As Its Shares Slump 25%
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) 30% Jump Shows Its Popularity With Investors